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the KU Leuven. Dince the last World Symposium on Pulmonary Hypertension in 2008, we have witnessed numerous and exciting
developments in chronic thromboembolic pulmonary hypertension (CTEPH). Emerging clinical data and advances in
technology have led to reinforcing and updated guidance on diagnostic approaches to pulmonary hypertension,
guidelines that we hope will lead to better recognition and more timely diagnosis of CTEPH. We have new data on
treatment practices across international boundaries as well as long-term outcomes for CTEPH patients treated with
or without pulmonary endarterectomy. Furthermore, we have expanded data on alternative treatment options for
select CTEPH patients, including data from multiple clinical trials of medical therapy, including 1 recent pivotal trial,
and compelling case series of percutaneous pulmonary angioplasty. Lastly, we have garnered more experience, and
on a larger international scale, with pulmonary endarterectomy, which is the treatment of choice for operable
CTEPH. This report overviews and highlights these important interval developments as deliberated among our task
force of CTEPH experts and presented at the 2013 World Symposium on Pulmonary Hypertension in Nice, France.
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is a potentially curable cause of pulmonary hypertension
(PH). In the previous 4th World Symposium on Pulmonary
Hypertension at Dana Point, California, in 2008, this topic
was addressed in 2 overlapping task forces: 1) Interventional
and Surgical Modalities of Treatment in Pulmonary Hyper-
tension; and 2) Diagnosis, Assessment, and Treatment of
Non-PAH Pulmonary Hypertension (1,2). For the current
symposium, a separate dedicated task force consisting of
experts from both medical and surgical specialties was estab-
lished to focus on this unique and important cause of PH.
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late future directions. To facilitate these goals, this panel
proposed and explored 4 key clinical topics germane to
CTEPH at the present time.
CTEPH Diagnosis
Over the years, there have been numerous and evolving
versions of diagnostic algorithms for the evaluation of PH.
These algorithms have consistently recommended the use of
a radionuclide ventilation/perfusion (VQ) scan to screen for
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and Acronyms
ACP = antegrade cerebral
perfusion
CT = computed tomography
CTEPH = chronic
thromboembolic pulmonary
hypertension
CTPA = computed
tomography pulmonary
angiogram
DHCA = deep hypothermic
circulatory arrest
ECMO = extracorporeal
membrane oxygenation
MRI = magnetic resonance
imaging
PAH = pulmonary arterial
hypertension
PAP = pulmonary artery
pressure
PEA = pulmonary
endarterectomy
PH = pulmonary
hypertension
PTPA = percutaneous
transluminal pulmonary
angioplasty
PVR = pulmonary vascular
resistance
RCTs = randomized
controlled trials
VQ = ventilation/perfusion
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D93computed tomography (CT) and magnetic resonance
imaging (MRI), the VQ scan remains the preferred test for
screening for chronic thromboembolic disease, and it should
be viewed as an initial step in the diagnosis of CTEPH
(Fig. 1). The limitations of using computed tomography
pulmonary angiogram (CTPA) for detecting chronic
thromboembolic disease were highlighted in the report from
Tunariu et al. (7). They reported a sensitivity rate of de-
tecting chronic thromboembolic disease of just 51% with
CTPA versus >96% with a VQ scan.
VQ scan remains the preferred test for screening for
additional reasons. Compared with CTPA, a VQ scan
requires less radiation exposure, avoids potential com-
plications related to intravenous contrast, and offers poten-
tial cost beneﬁts with less likelihood for detection of
incidental ﬁndings (8). In addition, interpretation requires
less additional training beyond what is currently demanded
for interpreting a VQ scan. In other words, perfusion defects
onVQ scan appear identical for either pulmonary embolism or
chronic disease (9). However, with CTPA, the defects in
chronic disease usually have a different appearance than
pulmonary embolism, hence requiring additional training and
attention to detect such differences (10). An additional
concern regarding reliance on CTPA for screening PH
includes false-positive cases from conditions mimicking
chronic thromboembolic disease. These conditions include
proximal lining thrombi associated with pulmonary arterial
hypertension (PAH) or congenital heart defects (11).
Pulmonary artery sarcoma can also be mistaken for chronic
thrombus (12). Therefore, overreliance on CTPAmay lead to
a false-positive diagnosis of chronic thromboembolic disease.
Another important concern regarding the reliance on
CTPA for screening and diagnosis of CTEPH has to do with
operability assessment. CTPA detects chronic thromboem-
bolic disease in vessels often deemed accessible for experienced
pulmonary endarterectomy (PEA) surgeons (segmental, lobar,
or main pulmonary arteries). Disease conﬁned to the very
distal segmental or subsegmental pulmonary arteries (locations
more likely to be deemed inoperable)may bemissed if screened
by using CTPA. Indeed, even with the latest 320-slice CT
technology, the sensitivity for detecting chronic disease in the
segmental vessels was reportedly lower compared with
detection rates for disease found in the main or lobar branches
(86% vs. 97%, respectively) (13). Accordingly, for experienced
or higher-volume endarterectomy centers, CTEPH diag-
nosed by using CTPA will often be deemed technically
operable. Furthermore, reliance on CTPA for screening alone
may miss potentially inoperable patients with CTEPH who
should be considered for a trial of medical therapy or could
participate in an appropriate clinical investigation.
Underutilization of VQ scans in screening PH invites
potential misdiagnosis of PAH. In the recent report from
the Pulmonary Arterial Hypertension Quality Enhancement
Research Initiative registry, we learned that 43% of patients
in the registry with PAH never had a VQ scan leading up to
their diagnosis (14). When considering the lower sensitivityof CTPA in detecting CTEPH,
some of these patients presumed
to have PAH may in fact have
CTEPH. The report also dis-
closed that roughly one-third of
these caseswithout aVQscanwere
because the provider reported that
the scan was not relevant. There-
fore, in addition to the technical
and interpretive limitations of
CTPA over VQ scans in the
screening for CTEPH, there is
a need for ongoing physician
education and general emphasis of
best practice for the evaluation of
PH.
These limitations notwith-
standing, CTPA has some bene-
ﬁts over conventional pulmonary
angiography in the evaluation of
CTEPH. With an abnormal
screening VQ scan, the next
imaging step in diagnostic algo-
rithms recommends pulmonary
angiography for disease conﬁr-
mation (Fig. 1). With improving
generations of CT scanners, the
higher-resolution images provide
additional details such as vascular
wall thickness and surrounding
structures not appreciated by con-
ventional angiography (15,16).
Furthermore, CTPA avoids the
need for direct catheter access and the associated expertise
and capability to perform selective angiograms. Accordingly,
high-quality CTPA, especially at centers experienced with
chronic thromboembolic disease, may be a reasonable alter-
native to pulmonary angiography in the evaluation of
CTEPH. CT also has the advantage of revealing associated
ﬁndings suggestive of chronic thromboembolic disease such as
bronchial artery collaterals and amosaic perfusion pattern, and
itmay also serve to screen for underlyingmediastinal disease or
other conditions mimicking chronic thromboembolic disease
(17). Lastly, with promising modalities such as dual-energy
CT and lung perfusion MRI, the innovation and growth
potential in pulmonary vascular imaging seem assured (18,19).
Despite these advances in CT and MRI scans, catheter-
based selective pulmonary angiography (particularly incor-
porating digital subtraction angiography to improve vessel
contrast) remains the gold standard for diagnosis and
conﬁrmation of chronic thromboembolic disease, and it is
the reference technique by which other imaging modalities
are compared in CTEPH (20,21). A major advantage
with catheter-based pulmonary angiogram is the ability to
combine the imaging with assessment of hemodynamic
parameters by using right heart catheterization. The
Figure 1 Diagnosis of CTEPH Leads to Operative Assessment
Diagnosis and treatment of CTEPH occur in a stepwise process, starting with an
echocardiogram and ventilation-perfusion scan. Diagnostic conﬁrmation requires
high quality pulmonary angiogram and right heart catheterization to assess the
location of chronic thromboembolism and severity of PH, respectively. The
pulmonary endarterectomy operability assessment depends on numerous factors
which contribute to overall risk assessment. CTEPH ¼ chronic thromboembolic
pulmonary hypertension; CTPA ¼ computed tomography pulmonary angiogram;
MRA ¼ magnetic resonance angiogram; VQ ¼ ventilation/perfusion.
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D94amount of contrast can be tailored by using cardiac output
measurement to produce optimum image quality while
minimizing contrast exposure. The angiographic appear-
ance and distribution, such as subpleural perfusion score
(i.e., qualitative measurement of pulmonary angiographic
“pruning”), has been associated with postoperative
outcomes (22). The comparison of radiographic burden of
disease with hemodynamics is a critical exercise in deter-
mining operability as well as surgical risk before PEA (23).
Ultimately, however, the overall operability assessment also
needs to incorporate patient factors such as comorbidities
and the experience level of the PEA surgeon and supporting
CTEPH team.
Recommendations regarding CTEPH diagnosis are thus
as follows:
 VQ scan is the preferred and recommended screening
test for chronic thromboembolic disease in patients
with PH. CTPA for screening may lead to potential
misdiagnosis of PAH and underdiagnosis of CTEPH,
including patients with distal disease.
 Pulmonary angiography (digital subtraction angiog-
raphy) remains the gold standard for conﬁrmation of
chronic thromboembolic disease and evaluation of
operability.
 High-quality multidetector CTPA may be a suitable
alternative to pulmonary angiography in centers with
experience in CTEPH.Updates on Surgical Therapy
The standard surgical technique for PEA has not changed
in the last 5 years. It is based on the principles established
by the group from San Diego (24). A median sternotomy
is essential to approach both lungs and cardiopulmonary
bypass and cooling to 20

C to allow arrest of the cir-
culation. Deep hypothermic circulatory arrest (DHCA)
is necessary to provide a clear operating ﬁeld to enable
a complete endarterectomy with dissection into sub-
segmental branches. This technique has proven safe and
reproducible and is used at most centers performing PEA
surgery. Indeed, the latest series from San Diego reported
an in-hospital mortality of 2.2% in the last 500 consecutive
patients (25). In the European CTEPH registry, with 17
surgical centers, the in-hospital mortality was 4.7% despite
some centers having low volumes and less experience (26).
However, there have been a series of reports, from Europe,
indicating that PEA is possible without complete DHCA
and another recommending multiple episodes of brief
DHCA (27–31). These have served to stimulate debate
about the technique and question if they can be improved
further. Can DHCA be reduced or even avoided? Is there
subtle cognitive injury with DHCA, and is there any
beneﬁt in attempting to maintain some brain perfusion?
More fundamentally, the purpose of the procedure is to
reduce pulmonary vascular resistance (PVR), and it is not
certain whether a complete endarterectomy is feasible in all
patients without DHCA.
The PEACOG (Circulatory Arrest Versus Cerebral
Perfusion During Pulmonary Endarterectomy Surgery)
study attempted to answer these questions (32). In this
prospective controlled trial, patients were randomized to
undergo the PEA operation with DHCA or antegrade
cerebral perfusion (ACP) with maintained brain blood ﬂow.
Cognitive function was assessed with multiple tests by
a blinded independent observer before surgery and at
3 months and 1 year after surgery. This trial was the ﬁrst
direct comparison of DHCA and ACP in any surgical
procedure, the largest trial involving DHCA in adults, and
the most complete evaluation of cognitive function after
PEA. Seventy-four patients were randomized to receive
treatment, with only 1 death in the hospital (1.4%), and
1-year survival was 96%. The ﬁndings with respect to
cognitive function were unexpected. At 3 months and 1 year,
there was no difference between the groups and, more
importantly, the mean scores in both groups for the main
parameters actually improved after surgery. This ﬁnding was
probably a result of improved cardiac output. The results did
not change when analyzed on a per-protocol or intention-
to-treat basis. Importantly, 9 patients had to cross over
from the ACP to the DHCA group to complete the PEA
because vision in the operating ﬁeld was compromised
without complete circulatory arrest. Therefore, patients and
referring physicians can be reassured that the current PEA
procedure is safe and does not cause impairment of cognitive
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DHCA. Surgeons can be conﬁdent that the standard
DHCA procedure is the best technique to allow a complete
endarterectomy, and this remains the recommended proce-
dure. Any further modiﬁcations should be compared directly
with this standard, preferably in a randomized controlled
setting.
Despite the improvements in outcome, there are speciﬁc
complications that account for the majority of deaths after
surgery: residual PH and reperfusion lung injury. The 2 are
often present in combination, and when severe, conventional
therapy has proved ineffective. As the technology of extra-
corporeal membrane oxygenation (ECMO) support has
improved in the last few years, it has been used for PEA
patients. Venoarterial ECMO is necessary if there is
hemodynamic instability, and the rationale is uniquely
appropriate for the pathophysiology. It can be used both
centrally with cannulation of the heart or peripherally with
cannulation of the femoral vessels. Blood is diverted away
from the right heart and lungs, allowing reduction in
pulmonary artery pressure, ofﬂoading the right ventricle; at
the same time, the ECMO circuit provides cardiac output
and gas exchange. For reperfusion injury alone, veno-venous
ECMO support is sufﬁcient. The important principle for
ECMO use is fulﬁlled as recovery can occur within the
time frame of potential support. To date, 3 publications
have reported on ECMO after PEA. Some have reserved
ECMO for patients with severe reperfusion lung injury
who have had a good hemodynamic result from PEA (33).
Other groups have used ECMO for hemodynamic support
in patients with right ventricular failure (34,35). Average
support duration is a median of 5 days in most series, and
reported survival is up to 57% (35). In the last 2 years, there
have been 4 additional case reports of ECMO use (36–39).
It is estimated that many of the patients described in these
series would have died without ECMO, and it is therefore
recommended as a standard of care for PEA centers to have
salvaging ECMO capability for the most severe complica-
tions after PEA.
The primary treatment for patients with CTEPH
remains surgical. However, since the original publication on
percutaneous pulmonary angioplasty in 2001, there had
been no further reports until 2012 when 3 reports emerged
from Japan (40–43). In total, there are now data published
on 127 patients. In some reports, the procedure was reserved
for patients who were not felt to be surgical candidates, but
in others a surgical opinion was not documented. Some
reports indicated that patients had “distal” disease and some
had “operable” disease, but comorbidity precluded PEA.
Some of the images within the publications demonstrate
that the vessels opened were of a size that arguably could be
treated surgically with PEA. The patients studied were
more likely to be female (>78%), whereas CTEPH typically
has no sex predilection, thus suggesting selection bias.
Common to all the series is the need for multiple angio-
plasty procedures within the same patient to achievebeneﬁcial results. The reported hemodynamic results are
impressive and represent hemodynamic improvements of
the magnitude obtained with PEA by experienced centers.
Furthermore, improvements in 6-min walk distance and in
World Health Organization functional class have also been
observed (43).
However, there are numerous concerns and unanswered
questions about this technique for the treatment of
CTEPH. First, clariﬁcation is needed to address the patient
selection process for this therapy over established and
potentially curative PEA. This technique also requires
multiple procedures, each with risks of complications, the
most severe being vessel rupture and reperfusion lung injury.
In addition, the procedure is currently limited, with a rela-
tively short follow-up compared with PEA. The durability
of the procedure and the risk of restenosis need to be
systematically evaluated and established. Hence, based on
the evidence to date, the role of percutaneous pulmonary
angioplasty in CTEPH remains uncertain and requires
further evaluation before it can be recommended as an
established treatment for CTEPH.
Recommendations regarding updates on surgical therapy
are thus as follows:
 PEA with DHCA remains the standard and recom-
mended operative technique for the treatment of
CTEPH.
 ECMO can be helpful as a supportive measure for
patients with severe postendarterectomy complications
and should be a standard of care in PEA centers.
 The role of percutaneous pulmonary angioplasty needs
to be further evaluated and should not replace PEA for
the treatment of CTEPH.
 A CTEPH team, consisting of an experienced PEA
surgeon and CTEPH physicians, should assess oper-
ability before alternative treatments are considered.
Close working collaboration between community
providers and CTEPH centers is required.Role of Medical Therapy
There are compelling reasons for considering PAH-
targeted therapies in CTEPH. The histopathological
examination of distal arteries in CTEPH patients reveals
vascular changes similar to those in patients with idio-
pathic PAH (44). As in PAH, plasma levels of
endothelin-1 closely correlate with the hemodynamic and
clinical severity of disease (45,46); a signiﬁcant number of
operated patients have persistent PH; and there are
CTEPH patients whose condition is inoperable (47). In
the large European CTEPH registry, 17% of the patients
had persistent PH deﬁned by a mean PAP >25 mm Hg
at the last measurement in the intensive care unit, and
37% of patients referred to the participating centers were
considered inoperable, mainly because of anatomically
peripheral disease deemed inaccessible, comorbidities, and
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lesions.
There is mounting evidence that PAH-targeted medical
therapy may have a role in the treatment of select CTEPH
patients. Patients deemed inoperable due to peripheral
disease and patients with residual or persistent PH after
PEA are in need of effective therapy. Numerous open-label
and several randomized controlled trials (RCTs) of 3 to
6 months’ duration have reported varying degrees of efﬁcacy
with medical therapy (Table 1) (48–60). Recognizing that
the treatment of choice and the only potential for cure
remains PEA, the 2 largest RCTs to date devoted to
CTEPH included an operability adjudication process.
The ﬁrst large-scale RCT in CTEPH was the BENEFiT
(Bosentan Effects in Inoperable Forms of Chronic
Thromboembolic Pulmonary Hypertension) study with
bosentan (58). A total of 157 patients with inoperable
CTEPH, including 28% with previous PEA, were ran-
domized to receive either placebo or bosentan and were
studied for 16 weeks. The study observed mixed results in
its 2 co-primary endpoints: 6-min walk distance in meters
was unchanged, with a treatment effect of 2 m (95%
conﬁdence interval: –22 to 27; p ¼ 0.5449), whereas PVR
reduction was achieved with a treatment effect of –24%
(95% conﬁdence interval: –32 to –16; p < 0.0001).
In the most recent and largest RCT of medical therapy
in CTEPH to date, the CHEST-1 (Chronic Thomboem-
bolic Pulmonary Hypertension Soluble Guanylate Cyclase-
Stimulator Trial-1) study with riociguat became the ﬁrst to
achieve clinically meaningful primary endpoints (60).
Riociguat is an oral therapy taken 3 times a day and belongs
to a novel class of soluble guanylate cyclase stimulators. In
CHEST-1, a total of 261 patients with prospectively adju-
dicated, inoperable CTEPH, including 27% with previous
PEA, were randomized 2:1 to receive either riociguat or
placebo, respectively. The study used a cautious drugTable 1 Short-Term (3 to 6 Months) Effects of Medical Treatment in
First Author (Ref. #), Year
Study
Design Duration
Epoprostenol (IV) Cabrol et al. (48), 2007 – 3 months
Treprostinil (SC) Skoro-Sajer et al. (49), 2007 – 6 months
Iloprost (inh) Olschewski et al. (50), 2002 RCT 3 months
Sildenaﬁl (PO) Ghofrani et al. (51), 2003 – 6 months
Sildenaﬁl (PO) Reichenberger et al. (52), 2007 – 3 months
Sildenaﬁl (PO) Suntharalingam et al. (53), 2008 RCT 3 months
Bosentan (PO) Hoeper et al. (54), 2005 – 3 months
Bosentan (PO) Hughes et al. (55), 2005 – 3 months
Bosentan (PO) Bonderman et al. (56), 2005 – 6 months
Bosentan (PO) Seyfarth et al. (57), 2007 – 6 months
Bosentan (PO) Jais et al. (58), 2008 RCT 4 months
Riociguat (PO) Ghofrani et al. (59), 2010 – 3 months
Riociguat (PO) Ghofrani et al. (60), 2013 RCT 4 months
*Mean  SD or median (interquartile range) in meters. Pulmonary vascular resistance (PVR) dyn$s/cm5 i
treatment effects for select CTEPH patients, including the four randomized controlled trials noted under
CTEPH ¼ chronic thromboembolic pulmonary hypertension; inh ¼ inhaled; IV ¼ intravenous; NYHA ¼
PO ¼ per os; RCT ¼ randomized controlled trial; SC ¼ subcutaneous; T ¼ total pulmonary resistance (mup-titration scheme to offset systemic vasodilatory effects.
At the end of 16 weeks, the treatment group was observed to
have a 46-m improvement in the primary endpoint of 6-min
walk distance (95% conﬁdence interval: 25 to 67; p < 0.001).
In addition, PVR was the ﬁrst in a series of hierarchical
secondary endpoints and saw a placebo-adjusted treatment
effect of –31% with therapy (p < 0.001). Additional positive
secondary endpoints included N-terminal pro–B-type
natriuretic peptide and World Health Organization func-
tional class. However, no signiﬁcant effect on time to clinical
worsening was observed. In the subgroup analysis, the
treatment effects were less pronounced in patients with
persistent PH after PEA. The safety proﬁle seems satisfac-
tory even if an increased incidence of hemoptysis was
observed in the double-blind period and in the open-label
continuation study. Riociguat is approved by the U.S.
Food and Drug Administration for PAH and CTEPH
patients and is currently undergoing the regulatory approval
process by the European Medicines Agency for both
indications.
As with previous guidelines, medical therapy in CTEPH
should not be considered as a replacement for PEA. The
evidence for medical therapy has all speciﬁcally focused
on a subset of CTEPH patients with either peripheral disease
that PEA specialists deemed inoperable or those patients with
recurrent or residual PH after PEA. Accordingly, the critical
step in the CTEPH treatment algorithm remains the opera-
bility assessment by a CTEPH team (Fig. 2). Because the
operability assessment remains complex, we recommend that
only an experienced CTEPH team should determine that
a case of CTEPH is inoperable. Furthermore, recognizing the
subjective nature of the operability assessment process, we
encourage a re-evaluation of operability by a second experi-
enced CTEPH center, whenever feasible, in cases initially
deemed inoperable. In cases of operable CTEPH, medical
treatment is associated with delays with PEA, and it adds noCTEPH
n NYHA 6MWD* Effect PVR Effect
23 III–IV 280  112 66 (T) 29  7y 21%
25 III–IV 260  111 59 924  347 13%
57 III–IV NA NS NA NS
12 NA 312  30 54 1,935  228z 30%
104 II–IV 310  11 51 863  38 12%
19 II–III 339  58 18 (NS) 734  363 27%
19 II–IV 340  102 73 914  329 33%
20 II–IV 262  106 45 (T) 1,165  392 21%
16 II–IV 299  131 92 712  213 NA
12 III 319  85 72 1,008  428 NA
157 II–IV 342  84 2 (NS) 783 (703–861) 24%
41 II–III 390 (330–441) 55 691 (533–844) 29%
261 II–IV 347  80 46 787  422 31%
n yWoods unit, dyn$s/cm5/m2. This table summarizes the results from published reports of medical
study design.
New York Heart Association functional class; 6MWD ¼ 6-min walk distance; NA ¼ not applicable;
ean  SD or median).
Figure 2 CTEPH: Treatment Algorithm
Once the diagnosis of CTEPH is made, all patients should receive life-long anticoagulation therapy unless contraindicated. All patients with CTEPH should be referred for
operability assessment by an experienced CTEPH team to determine if the patient is operable and candidate for pulmonary endarterectomy. If a patient is deemed non-operable,
we recommend consideration for a second opinion by an experienced CTEPH team. This recommendation is in recognition of operability deﬁnition being subjective and
dependent on center experience, and mirroring the operability adjudication process utilized in recent randomized controlled trials of medical therapy. For patients deemed non-
operable, or patients after pulmonary endarterectomy with persistent symptomatic PH, treatment with PH targeted medical therapy is recommended. Other treatment options in
select cases may include lung transplantation or percutaneous transluminal pulmonary angioplasty. PTPA ¼ percutaneous transluminal pulmonary angioplasty; other abbre-
viations as in Figure 1.
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D97beneﬁt (61). Therefore, PAH-targeted medical therapy in
operable cases of CTEPH is not recommended. In addition
to the delay for deﬁnitive treatment with PEA, the potential
effects and risks of PAH-targeted therapies on the chronic
thromboembolic material or surgery have not been
adequately evaluated.
Recommendations regarding the role of medical therapy
are thus as follows:
 The determination of operability is critical in CTEPH
and should only be conducted by an experienced
CTEPH team.
 For inoperable CTEPH and residual disease after
PEA, medical therapy is recommended. Riociguat is
the ﬁrst drug therapy to show positive primary
endpoints in an RCT for those indications.
 Operable CTEPH cases should be referred for PEA
without delay. The role of bridging with medical
therapy has not been sufﬁciently studied and should be
reserved for controlled investigation.Treatment Outcome Considerations
In the early years of PEA for CTEPH, reasonable alterna-
tive treatments did not exist. In addition, PEA operative
mortality was signiﬁcantly higher than seen in the modern
era. Accordingly, early or traditional focus has been with
immediate postoperative hemodynamic improvement andin-hospital mortality (62). With increases in global aware-
ness and clinical activity in PH, we have witnessed a parallel
growth in the science and clinical experience of CTEPH.
New centers have begun performing PEA surgery, in part to
keep up with a growing demand of patients diagnosed with
CTEPH (63). At the same time, the experienced and
established centers are performing more surgeries, gaining
more experience, and, as a result, are improving their post-
operative outcomes (25). In anticipation and recognition of
this growth and trend, at the 4th World Symposium on
Pulmonary Hypertension in Dana Point, California, the
consensus recommendation was for PEA centers to achieve
and target a <7% in-hospital mortality rate (1). At this
point, we recommend revisiting these targets and endorse
additional treatment goals and expectations.
The European CTEPH registry has contributed valuable
information to help guide the ﬁeld of CTEPH going forward
(26,47). This registry combined 679 incident cases of
CTEPHdiagnosed from 1Canadian center and 26European
centers (including 17 PEA centers). The registry reinforced
the importance of PEA in the treatment of CTEPH and
improved surgical outcome based on center experience as
measured according to PEA cases performed per year. The
outcome data after PEA importantly went beyond the typical
in-hospital mortality and captured long-term mortality. The
difference in observed survival at 3 years was 89% for operated
CTEPH versus 70% for the nonoperated group (p< 0.0001)
(64). Similarly favorable long-term survival rates after PEA
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D98have been reported by Archibald et al. (65), and these results
re-emphasize the importance of surgical evaluation and
treatment for all patients with CTEPH.
Although long-term survival is of critical importance, it
may not be adequate without additional considerations.
For the individual patient with CTEPH, efﬁcacy of any
treatment should also demonstrate durability of beneﬁt
and improved quality of life. For the patient who undergoes
PEA, freedom from PAH-targeted therapy, oxygen sup-
plementation, or lung transplantation represents an impor-
tant measure of treatment success beyond in-hospital or
long-term survival. For cases of inoperable CTEPH, both
affected patients and treating clinicians want effective
treatment alternatives that will improve exercise capacity,
quality of life, and prolong survival, while posing minimal
adverse effects or risks from the therapy. At this time, the
cumulative evidence and experience unequivocally support
PEA as the treatment of choice in patients with operable
CTEPH. Accordingly, all cases of CTEPH should receive
operability assessment by a CTEPH team and PEA if
deemed operable.
Recommendations regarding treatment outcome consid-
erations are thus as follows:
 Operable CTEPH patients treated with PEA have
a better long-term survival rate than those deemed
inoperable and treated with medical therapy.
 Emerging PEA centers should strive to achieve early
hemodynamic improvements and low (<7%) in-hospital
mortality rates after PEA. However, the deﬁnition of
success of PEA needs to include long-term outcomes.
 CTEPH centers are encouraged to participate in
current and future collaborative studies to resolve
uncertainties in the understanding and treatment of
CTEPH, and adequately assess long-term outcomes.Reprint requests and correspondence: Dr. Nick H. Kim,
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